background the cimvhr tpl research initiative encourages researchers from relevant fields to submit project proposals to compete for access to funding to accelerate research and improve the health and wellbeing of canadian military, veterans, and their families.   this opportunity has been made possible through the support of true patriot love and the true patriot love fund. the true patriot love fund was established in january 2015 for the purposes of supporting research to discover new treatments, establish evidence-based programs, and increase access to programs and treatments dedicated to advancing the health and well-being of canadian military members, veterans, and their families. 

the main objectives of the cihr summer institute on equitable ai for public health funding opportunity, led by the host institution(s) are to:

• equip doctoral and post-doctoral trainees and early career researchers from primarily public health and, secondarily, computational sciences backgrounds with the technical skills to use ai approaches and methods to tackle key public health challenges;
• prepare participants to address the equity implications of different ai approaches, including identifying strategies to prevent and mitigate potential inequities that could result when using ai approaches in public health research and practice, and opportunities for leveraging ai to advance health equity;
• facilitate a high-quality, interdisciplinary learning environment that offers participants from across canada the opportunity to interact with others from a diverse range of backgrounds and disciplines within public health and computational sciences, as well as canadian and international leaders and implementers working in ai and public health; and
• catalyze the development of open-access training content and materials focused on using ai approaches in public health research that can be adapted and integrated into curricula for trainees at schools of public health and related disciplines, and among staff at public health agencies across canada.  

cardiovascular diseases (cvd) are a leading cause of death, one of the major causes of long-term sickness; chronic disease and loss to the labor market, and thus represent a major health and socioeconomic problem. development of new and innovative medicinal products and improvement in medical technology requires innovative research based on scientific excellence founded on a better understanding of the causes of cvd. cardiovascular research and its translation into better preventive, diagnostic and therapeutic outcomes are fundamental for patients.

funded under horizon 2020, the aim of the european research area network on cardiovascular diseases (era-cvd) is to foster transnational collaboration of european countries and beyond, and to coordinate research efforts and funding programs of its partner countries. cihr-icrh is collaborating with other era-cvd partners to fund canadian researchers through jtc2019.

jtc2019 is the forth joint transnational call from era-cvd. jtc 2019 aims at enabling early career scientists in different countries to build an effective collaboration on common multidisciplinary research projects. the consortia should be based on complementarities and sharing of expertise in the field of cardiovascular disease, with a clear translational research approach. the call aims to promote cooperation and interchange between early career scientists and thus enable international collaboration and new consortia establishment in cardiovascular research. in this call, it is possible for consortia to include one senior/established scientist (see eligibility) who may not be the coordinator of a consortium.

applications will be complementary and contain novel, ambitious ideas to answer key questions or lead to a step-wise change in understanding of cvd topics. there should be a clear added value in funding the collaboration over individual projects by sharing of resources (e.g., models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc. the research proposals should be built on an effective collaboration among the different research participants from different countries. each transnational consortium should represent the critical mass necessary to achieve ambitious scientific goals.

neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. worldwide, there are estimated to be 47 million people suffering from alzheimer’s disease and related disorders, the most common class of neurodegenerative diseases. this figure is expected to double every 20 years as the population ages. existing treatments for neurodegenerative diseases are limited in effect and mainly address the symptoms rather than the cause or the progressive course. in this context, the eu joint programme – neurodegenerative disease research (jpnd) was established in order to better coordinate research efforts across countries and disciplines to more rapidly find causes, develop cures and identify better ways to care for people with neurodegenerative disease. the jpnd research and innovation strategy, published in 2012 and refreshed in 2018, identified research priorities and provided a framework for future investment.

one of the greatest challenges for treating neurodegenerative diseases is the deciphering of this variability, which can be addressed through personalised medicine. “personalised medicine,” as defined by the horizon 2020 advisory group, “refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g., molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.”

the goal of this call multinational research projects on personalised medicine for neurodegenerative diseases (jpco-fund) is to increase the number of high quality transnational scientific projects. these projects must demonstrate clear scientific added value from working across national borders.

proposals to be funded under this call will need adequately to involve patients, carers and the public. consortia are expected to make every effort to include approaches on patient and public involvement, where appropriate, at each stage of the research process including the preparation of the application.

era permed will foster research and innovation activities building close linkages between basic biomedical research, clinical research, bioinformatics, epidemiology, socio-economic research, as well as research on the integration of personalised medicine into clinical practice and on ethical, legal and social implications. the overarching goal is to improve disease management, with better patient stratification, diagnostics and treatment protocols, and disease prevention. proposals submitted under this call are expected to demonstrate the applicability of project outcomes into clinical practice as well as to describe the impact on the health care systems. proposals are expected to include research on ethical, legal and socio-economic implications, including health economics and regulation, and/or research on optimisation of health care systems.

the sickkids foundation–cihr-ihdcyh new investigator research grants in child and youth health in child and youth health program seeks to strengthen canada’s capacity and knowledge to respond to children’s health challenges and needs. the grants are jointly sponsored by sickkids foundation and the cihr institute of human development, child and youth health (ihdcyh). new investigators (also referred to by cihr as early career investigators) may obtain up to three years of support for research in biomedical, clinical, health systems and services, population and public health sectors that has the potential for significant impact on children’s health outcomes.

the aim of the sickkids foundation–cihr-ihdcyh new investigator research grants in child and youth health program is to provide important early career development support to child health researchers and enhance their ability to compete for future research grants.

established in 1984, the law for the future fund (lfff) provides financial support for canadian research projects of national interest that are of benefit to the general public.

since its foundation, the lfff has helped finance more than 175 innovative and timely research projects. they include issues such as the recognition of environmental rights, access to justice in civil and family matters, prostitution laws and women's equality rights, the simplification of basic principles of human rights, and ways to make legal organizations more accessible to persons with disabilities.

the board of directors meets two times per year to oversee the operation of the fund and to consider fundraising issues. to date, the total assistance granted by the lfff is well over $3 million. the deadline for applications is the 1st of may each year.

funding (up to $1,500,000 over up to 3 years) for transformative, novel, high-risk, high-reward translational research projects on neurodegenerative diseases of aging. preliminary data is not required. other lifestyle interventions are now eligible for funding if they meet our other scope criteria and there is specific supportive evidence/justification to warrant further investigation. cycles of this program will run back-to-back going forward.

funding (up to $1,500,000 over up to 3 years) for transformative, novel, high-risk, high-reward translational research projects on neurodegenerative diseases of aging. preliminary data is not required. other lifestyle interventions are now eligible for funding if they meet our other scope criteria and there is specific supportive evidence/justification to warrant further investigation. cycles of this program will run back-to-back going forward.

parkinson’s & related diseases (pd, psp, dlb, msa, prodromes, and vascular contributions to the listed diseases)
note: the program dates have been extended. the deadline for lois is now may 15, 2019.

rapid response: canada 2019

seed funding (up to $300,000 over up to 18 months) for novel, high-risk, high-reward translational research projects on neurodegenerative diseases of aging. preliminary data is not required. other lifestyle interventions are now eligible for funding if they meet our other scope criteria and there is specific supportive evidence/justification to warrant further investigation. cycles of this program will run back-to-back going forward.

alzheimer’s & related diseases (ad, ftd, mci, and vascular contributions and prodromes to the listed diseases)

program opens: currently open
loi deadline: april 1, 2019